1.Effect of Endothelial Progenitor Cell Transplantation on Pulmonary Hypertension in Rats
Lian-Man HE ; Jun HUANG ; Jing XIAO ; Jun-Fang WU ;
Chinese Journal of Hypertension 2006;0(12):-
Objective To investigate the hemodynamics and structural effect of rat endothelial progenitor cells (EPC) transplant on pulmonary artery hypertension (PAH) induced by monocrotaline(MCT) in rats.Methods EPCs were identified and marked.Twenty-one days after injection of EPCs,the pulmonary hemodynamic parame- ters,average pulmonary artery pressure (mPAP),right heart index were determined.The vascular endothelial cells and pulmonary vascular structural changes were verified by fluoresccuse microscope.Results Compared with the model,EPCs treatment(n=10) decreased mPAP significantly (mPAP,EPCs:25.9?0.7 mmHg vs model group:29.3?2.2 mmHg,P
2.Telmisartan Prevent Oxidative Injuries in Endothelial Cells Induced by High Glucose
Jun HUANG ; Jing XIAO ; Lian-Man HE ; Hai-Yan QIN ; De-Qiang LI ;
Chinese Journal of Hypertension 2007;0(04):-
Objective To investigate the effect of telmisartan on the oxidative stress induced by high glucose in human umbilical vein endothelial cell (HUVEC) in vitro.Methods HUVEC were cocultured with telmisartan (1?10~(-6) mol/L) and various concentration of glucose(5,30 mmol/L) for 0,12,24,36,48 h respectively. The level of MDA in the supernatants of cultured endothelial cells was measured by thiobarbituric acid test,SOD was determined by xanthine oxidase test.The protein expression of peroxisome proliferator activated receptors ? (PPAR-?) in HUVEC 24 h was assessed by Western blot after treatments.Results High glucose significantly increase the levels of MDA (before:1.2?0.06 vs after:1.6?0.1 mmol/mL,P
3.Allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia: a retrospective analysis from a single center
Min HE ; Qiqi YI ; Hailing LIU ; Ding DING ; Man XU ; Guoli LIAN ; Xiaoning WANG
Chinese Pediatric Emergency Medicine 2024;31(7):507-511
Objective:To evaluate the clinical efficacy of allogeneic hematopoietic stem cell transplantation(allo-HSCT)in children with severe aplastic anemia(SAA).Methods:Twenty-seven cases with SAA who had been treated with allo-HSCT from January 2020 to December 2022 were retrospectively analyzed and reviewed.Results:(1)A total of 27 SAA patients were enrolled,including 18 males and 9 females,with a median age of 8 (2-15) years.There were 20 cases of SAA-Ⅰ type,7 cases of SAA-Ⅱ type.Based upon donor sources,three cases of matched sibling donors hematopoietic stem cell transplantation,and 24 cases of haploidentical hematopoietic stem cell transplantation were adopted.(2)Hematopoietic reconstruction was achieved in all 27 cases.The median implantation time of neutrophils and platelets was 10(9-20)days and 12(7-26)days respectively.The cumulative incidence of acute graft-versus-host disease(GVHD)was 66.67%(18/27).The incidence of grade Ⅰ-Ⅱ was 55.56%(15/27)and that of grade Ⅲ-Ⅳ was 11.11%(3/27).The incidence of chronic GVHD was 7.41%(2/27).Transplant-associated thrombotic microangiopathy (TA-TMA) occurred in 7.41%(2/27)patients,cytomegalovirus viremia in 62.96%(17/27)patients,epstein-barr virus infection in 33.33%(9/27)patients,and 14.81%(4/27)patients progressed to post-transplant lymphoproliferative disorder (PTLD).(3)The median follow-up time was 12 (2-28) months.The overall survival rate was 96.29%.Twenty-six patients survived,and one patient died due to multiple complications of severe acute GVHD,TA-TMA,cytomegalovirus infection,PTLD and secondary epilepsy.Conclusion:Allo-HSCT is an effective therapy for SAA in children.The effective rate of this research is 96.29%.Acute GVHD is still the key to therapy.The incidence rate of acute GVHD is 66.67% in this study.The blood incompatibility of donor and recipient may affect the incidence of GVHD.The intensity of GVHD prevention should be reduced after HLA-matched sibling donor-hematopoietic stem cell transplantation so as to avoid the complications of virus recurrence and PTLD.
4.Discovery and activity verification of reniformin A as an anti-tumor leading compound.
Man GONG ; Lian-He YANG ; Li-Li ZHU ; Qing-Mei FENG ; Er-Ping XU ; Li-Ping DAI ; Zhi-Min WANG
China Journal of Chinese Materia Medica 2021;46(16):4061-4068
Reverse prediction and molecular docking techniques were employed to evaluate the feasibility of reniformin A(RA) as an anti-tumor leading compound. Based on the reverse prediction, network pharmacology was used to construct a "disease-compound-target-pathway" network. Thirty-nine tumor-related targets of RA were predicted, which participated in the regulation of multiple cellular activities such as apoptosis, cell cycle, and tumor metastasis, and regulated estrogen signal transduction and inflammatory response. Discovery Studio 2020 was adopted for molecular docking and toxicity prediction(TOPKAT). As revealed by the results, the binding affinity of RA with the tumor-related targets ABL1, ESR1, SRC and BCL-XL was stronger than that of oridonin(OD), while its mutagenicity, rodent carcinogenesis, and oral LD_(50) in rats were all inferior to that of OD. Furthermore, in vitro experiments were performed to confirm the anti-tumor activity of RA, and the mechanism was preliminarily discussed. The results demonstrated that RA was superior to OD in cytotoxicity, inhibition of cell colony formation, and induction of apoptosis. RA, possessing potent anti-tumor activity, is expected to be a new anti-tumor leading compound.
Animals
;
Drugs, Chinese Herbal/pharmacology*
;
Lead
;
Molecular Docking Simulation
;
Neoplasms/genetics*
;
Rats
;
Signal Transduction